Walvax BioTech (300142 SHE) stock market data APIs
¥12.2429
0.06(0.5%)
as of September 18, 2025
Try our APIs with
free plan!
Walvax BioTech Financial Data Overview
Price chart is built with
Anychart
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The company was founded in 2001 and is headquartered in Kunming, China.
Prev. Close
12.2429
Open
12.3031
High
12.5722
Low
12.0199
52 wk Range
9.6905-18.9614
Market Cap
19 560 M
P/E Ratio
1223
Shares Outstanding
1 599 M
Revenue
2 542 M
EPS
0.03
Dividends (Yield)
0.0008
Beta
0.394
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Walvax BioTech (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Walvax BioTech data using free add-ons & libraries
Get Walvax BioTech Fundamental Data
Walvax BioTech Fundamental data includes:
- Net Revenue: 2 542 M
- EBITDA: 259 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-25
- EPS/Forecast: 0.11
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Walvax BioTech News
New
3 Global Stocks Trading Below Estimated Value In September 2025
As global markets navigate a landscape marked by modest declines in major U.S. indices, mixed performances in Europe and Japan, and a rally in Chinese stocks fueled by domestic liquidity, investors ar...
FOCUS-China's drugmakers can't sell mRNA shots but haven't quit yet
By Andrew Silver SHANGHAI/SUZHOU, China, April 19 (Reuters) - China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messen...
Indonesia Approves Chinese mRNA Vaccine
Indonesia became the first country to give regulatory go-ahead to a Chinese-made mRNA Covid-19 vaccine for emergency use, marking potential progress in Beijing’s push to catch up with Western vaccine technology. Continue reading
Chinese mRNA COVID booster stronger against Omicron than Sinovac shot -trial data
BEIJING, June 1 (Reuters) - A COVID-19 vaccine candidate from China's Walvax Biotechnology using mRNA technology triggered a stronger antibody response against the Omicron variant of the coronavirus a...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
